The updated Medscheme specialised drug list for 2023 has been published
Reimbursement is still dependent on authorisation and benefit limits.
Some drugs included:
ANTIHEMORRHAGICS
Hemlibra
CARDIOVASCULAR SYSTEM
Volibris
DERMATOLOGICALS
Dupixent
ANTIVIRALS FOR SYSTEMIC USE
Epclusa
ANTINEOPLASTIC AGENTS
Blitzima and Ristova (Rituximab)
Plegridy
IMMUNOSUPPRESSANTS
Myelenea and Filengia (Fingolimod)
Unamity
Tremfya
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xolair
Recent Posts
Methodological Gaps in Economic Evaluations of Vaccines: A Systematic Review
Economic evaluations of vaccines targeting multi-disease combinations, such as hepatitis A/B or measles-mumps-rubella (MMR), reveal critical methodological shortcomings in this systematic literature review. Synthesiz...
Aspen Pharmacare Financial Growth: Navigating H1 2026’s Transitional Financial Landscape
Aspen Pharmacare Financial Growth Powers Through Strategic Shifts
Aspen Pharmacare's financial growth shines in its H1 2026 results, driven by resilient Commercial Pharmaceuticals,
South Africa’s Push for Local Lenacapavir Production to Enhance HIV Prevention
South Africa has launched a bold bid to enable local lenacapavir production, targeting the twice-yearly injectable long-acting HIV prevention drug from ...